Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
Carcinogenic survival assay results charting survival of PBRM1 / BAF180 knock-out cell lines with concentration intervals of the PARP inhibitor Olaparib, the POLA inhibitor Erocalciferol and the ABL inhibitor Dasatanib.
These results suggest PBRM1 mutant cells may be more sensitive to both the PARP and ABL1 inhibitors while gaining some resistance to POLA1 inhibition. Error bars measure standard error of measurement. All drug intervals are measured in mM.